FLT3 and acute myeloid leukemia: When FLT3-ITD AML patients treated with azacitidine combined with sorafenib, allelic burden and FLT3-ITD clone size were significantly reduced and progression-free survival (PFS) was significantly increased compared to sorafenib treatment alone [230].